But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s."Lilly is pulling ahead in the metabolic duopoly," BMO Capital Markets analyst Evan Seigerman said in a research note Thursday.
Unlike Novo Nordisk, Eli Lilly benefited from higher U.S. prices of Mounjaro in the quarter as use of savings card programs for the drug decreased. Executives said they expect"stable pricing" for Mounjaro and Zepbound across the last two quarters of 2024.Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.
In a research note Thursday, Bank of America analysts raised their combined revenue forecast for Mounjaro and Zepbound to $19.7 billion in 2024, $31 billion in 2025 and $38.5 billion in 2026 because they have"gotten more comfortable with supply dynamics." Eli Lilly expects incretin drug production – another term for weight loss and diabetes treatments – in the second half of 2024 to be 50% higher than it was during the same period last year, he added.
Stryker offers medical and surgical equipment and a range of products in orthopedics and neurotechnology. The company said technology like Care.ai's is of"increasing importance" as health-care organizations contend with challenges like nursing shortages, burnout, administrative burden and workplace safety concerns, according to a
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: nbcchicago - 🏆 545. / 51 Read more »
Source: Medscape - 🏆 386. / 55 Read more »